Quest Diagnostics Acquires Cleveland HeartLab, Formalizes R&D Collaboration

We represented Quest Diagnostics (NYSE: DGX) in its acquisition of Cleveland HeartLab. The acquisition combines the expertise of Cleveland HeartLab’s personalized evaluation of heart disease risk based on inflammation and other markers with Quest’s Cardio IQ® lipid particle analysis and genetic and metabolic testing leadership. In connection with the acquisition, Quest Diagnostics and Cleveland Clinic have also finalized a strategic collaboration intended to speed the commercialization of emerging innovations at Cleveland Clinic, including its Lerner Research Institute. Terms of the transaction were not publicly disclosed.

Quest Diagnostics is the world’s leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions.

You Also May Be Interested In:

  • Represented Wholesale, LLC and Wholesale Express, LLC in its sale to RumbleOn, Inc (Nasdaq: RMBL) for $16 million in cash and 1,317,329 in shares of RumbleOn Series B Preferred Stock

    We represented Wholesale, LLC. and Wholesale Express, LLC., an independent distributor of pre-owned vehicles in the US, in its sale...
    Client Type: Private Company
  • Represented Hibbett Sports (Nasdaq: HIBB) in Acquisition of City Gear

    We represented Hibbett Sports, Inc. (Nasdaq: HIBB) in its definitive agreement to acquire City Gear – a specialty athletic apparel,...
    Client Type: Public Company
  • Representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge with Strategic Storage Trust II, Inc., (SST II) in an all-cash merger valued at $340 million expected to close during the first quarter of 2019, subject to customary closing conditions, including the approval of SSGT’s stockholders

    We are representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge...
    Client Type: Private Company